



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

September 12, 2023: 6:00 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:40 - 6:45**

- **Chief Medical Officer Updates** **6:45 - 6:50**

- **Follow-up Items from Previous Meetings** **6:50 – 6:50**

- **RetroDUR/ProDUR** **6:50- 7:20**
 - Data presentation: Chronic Use of Sedatives/Hypnotics
 - Introduce: Proposed RetroDUR topics for 2024

- **Clinical Update: Drug Reviews** **7:20-7:40**
(Public comment prior to Board action)

- **Biosimilar Drug Reviews**
 - None at this time.

- **Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - Altuviiiio® (recombinant)
 - Atorvaliq® (atorvastatin calcium)
 - Austedo XR® (deutetrabenazine)
 - Brixadi™ (buprenorphine) extended-release injection
 - Daybue® (trofinetide)
 - Filspari® (sparsentan)
 - Leqembi® (lecanemab-irmb)
 - Pradaxa Pellets® (dabigatran etexilate)

- **New Managed Therapeutic Drug Classes** **7:40 -7:40**
 - None at this time.

- (Public comment prior to Board action)
 - None at this time

- **Therapeutic Drug Classes – Periodic Review** **7:40 - 8:30**
(Public comment prior to Board action)
 - Androgenic Agents
 - Antiemetics (new drug Aponvie® (aprepitant) included)
 - Pulmonary Agents (will include the following class reviews:
 - Bronchodilators: Beta Agonists
 - COPD Agents
 - Inhaled Glucocorticoids
 - Immunologic Therapies for Asthma
 - Growth Hormones (new drug Sogroya® (somapacitan-beco) included)

- **Review of Newly Developed/Revised Criteria** **8:20 - 8:30**
(Public comment prior to Board action)
 - Influenza Vaccines

- **General Announcements** **8:30 – 8:30**
 - None at this time.

- **Adjourn** **8:30**